What synthesis pages are
A synthesis page is a researcher-facing summary of a single TNBC topic, written by a domain-expert writer, reviewed by the editorial PI and a domain reviewer, and continuously revised as new evidence enters the bibliography. Each page:
- Cites primary literature inline for every substantive claim.
- Assigns an evidence grade (A–D, adapted from GRADE) to each claim.
- Maintains a versioned permalink history so earlier cited versions stay reachable.
- Cross-links to the corresponding patient-layer page when one exists.
- Lists open questions and ongoing trials at the bottom.
See the methods page for the underlying bibliography pipeline, and the errata and changelog for the editorial workflow and revision history.
Status of the taxonomy
45 drafted · 0 in progress · 0 planned · 45 total. Drafted pages are linked; the rest are listed by name with a status badge so the roadmap is visible. The full taxonomy is from the project’s Phase 2 plan and is versioned in the project repository.
Topic taxonomy
A Epidemiology and disparities
- Drafted
Worldwide TNBC burden, regional variation, secular trends.
- Drafted
BRCA1 prevalence, African-ancestry TNBC enrichment, sub-Saharan epidemiology, US racial disparities in outcomes.
-
Why TNBC over-represents women under 40 and the implications for screening.
-
Access, insurance, and outcome disparities orthogonal to biology.
B Biology and molecular subtypes
- Drafted
Researcher-layer companion to the patient-facing page. Cited primary literature throughout.
-
From Perou 2000 through PAM50 and modern intrinsic-subtype testing.
-
BL1, BL2, IM, M, MSL, LAR; subsequent four-subtype refinement.
- Drafted
BLIA, BLIS, MES, LAR; reconciliation with Lehmann/Pietenpol.
-
The TILs Working Group methods, prognostic and predictive value.
-
Germline and somatic biology, HRD scoring, treatment implications.
-
What single-cell transcriptomics and spatial methods have changed about how we think about TNBC.
C Diagnosis and pathology
-
ASCO/CAP testing standards; the HER2-low boundary; assay heterogeneity.
-
Subtype classifiers in practice; what tests are clinically actionable today.
-
CNN-based TIL quantification, pCR prediction from H&E, deployment maturity.
- Drafted
Mammography, MRI, ultrasound, and novel modalities; the imaging signature of TNBC.
D Treatment — early-stage
-
Trial design, results, EFS update, and open questions.
- Drafted
From Cortazar 2014 forward; surrogate-endpoint considerations for TNBC trials.
-
Capecitabine (CREATE-X), olaparib (OlympiA), emerging post-KEYNOTE-522 options.
- Drafted
Lumpectomy vs mastectomy, sentinel vs axillary, bilateral in BRCA carriers.
- Drafted
Hypofractionation, post-mastectomy decisions, regional nodal radiation.
E Treatment — metastatic
- Drafted
KEYNOTE-355, biomarker-driven selection, when PARP inhibitors come first.
- Drafted
Trial design, results, sequencing, side-effect management.
-
The reclassification of historically TNBC tumors and what it implies for biomarker testing.
-
OlympiAD, EMBRACA, sequencing decisions, beyond-BRCA expansion attempts.
-
Enzalutamide proof-of-concept and current trial landscape.
- Drafted
Epidemiology, prevention, treatment of established disease, CNS-penetrant agents.
F Immunotherapy
-
IMpassion130, IMpassion131, KEYNOTE-355, KEYNOTE-119, KEYNOTE-086, KEYNOTE-522.
-
CPS vs IC scoring, SP142 vs 22C3, what differences mean in practice.
-
IO + chemo, IO + PARP, IO + ADC, IO + radiation; the trial landscape.
G Computational / ML / AI
-
From clustering-on-bulk-RNA to multi-omics deep learning; what works and what doesn’t.
-
CNN-based whole-slide-image models, integration with biomarkers, deployment considerations.
- Drafted
The Halicin pattern applied to TNBC: graph neural networks, screening libraries, validation.
-
Joint models, fusion strategies, what each modality contributes.
H Clinical trial methodology
-
What each endpoint measures, the regulatory history, the surrogacy debates.
-
Bayesian adaptive randomization, drug graduation, lessons after a decade.
-
Basket and umbrella designs, biomarker-positive vs all-comer enrollment.
-
PRO measurement standards, what trials capture and what they miss.
I Survivorship and supportive care
- Drafted
Cardiotoxicity, lymphedema, cognitive changes, second cancers.
- Drafted
Evidence for and against routine imaging and tumor-marker testing in asymptomatic survivors.
- Drafted
Depression, anxiety, scan-related anxiety, intervention evidence.
- Drafted
Preservation options, timing, post-treatment pregnancy safety data.
J Patient experience and ethics
- Drafted
Decision-aid evidence, what works at the bedside.
- Drafted
Cost of new agents, financial toxicity, access programs.
-
Cascade testing, family communication, ethical frameworks.
-
Demographic gaps in enrollment, logistical barriers, equity-focused trial design.
Drafting and reviewing
Contributors and reviewers, see About & governance for the editorial workflow, conflict-of-interest policy, and how to join. The drafting handbook (style guide, evidence-grading rubric, citation-token format) is maintained in the project repository.
Last reviewed: 2026-05-18. This index updates whenever a topic page moves through draft → in-progress → drafted, or when the taxonomy itself changes (additions, splits, merges). Taxonomy changes are recorded in the errata and changelog.